Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.40 |
| ▸ | CDK9 | P50750 | 7/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9101391 | 0.97 | SCN9A (0.41) | USP30SCN9ACCNT1CDK9PARP1 | |
| SCHEMBL9101641 | 0.91 | CDK9 (0.38) | CCNT1CDK9 | |
| SCHEMBL9106308 | 0.91 | CDK9 (0.42) | CCNT1CDK9 | |
| SCHEMBL9103301 | 0.90 | CCNT1 (0.44) | CCNT1CDK9PARP1BRD4L3MBTL1 | |
| SCHEMBL9105945 | 0.90 | CDK9 (0.44) | CCNT1CDK9 | |
| SCHEMBL9104751 | 0.90 | CDK9 (0.40) | CCNT1CDK9 | |
| SCHEMBL9898441 | 0.89 | SCN9A (0.40) | USP30SCN9APARP1BRD4L3MBTL1 | |
| SCHEMBL9106967 | 0.89 | MEN1 (0.43) | PARP1L3MBTL1CCNCCDK8HASPIN | |
| SCHEMBL9107145 | 0.89 | SLC2A1 (0.41) | PARP1L3MBTL1CCNCCDK8HASPIN | |
| SCHEMBL9104252 | 0.89 | CDK9 (0.40) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8816085-B2 | Methylpyrrolopyridinecarboxamides | TAKEDA GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20120142633-A1 | METHYLPYRROLOPYRIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142633-A1 | METHYLPYRROLOPYRIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | USP30 2987/4885SCN9A 879/4885CCNT1 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.